News Scan for Jul 09, 2014

HPV vaccine and embolism
;
Dengue in Florida

Large study finds no elevated embolism risk with HPV vaccine

Although some studies have suggested that the quadrivalent (four-strain) human papillomavirus (HPV) vaccine may raise the risk of venous thromboembolism (VTE), which is a blood clot that lodges in a vein, a Danish study released today in JAMA of more than 500,000 girls and women who received the vaccine did not find an increased VTE incidence.

The population-based study included all 1,613,798 Danish girls and women aged 10 through 44 years from October 2006 through July 2013, of whom 500,345 (31%) received the HPV vaccine. The researchers identified 4,375 incident cases of VTE, 889 (20%) in vaccinated patients.

"There was no association between the quadrivalent HPV vaccine and VTE during the 42 days following vaccination (crude incidence rates, 0.126 and 0.159 events/person-year for risk and control periods, respectively; incidence ratio, 0.77)," the authors wrote.

They also found no association between the vaccine and VTE in subgroup analyses by age, including only anticoagulant-treated cases, only exposed cases, or when adjusting for oral contraceptive use.
Jul 9 JAMA research letter extract

 

Florida reports first locally acquired dengue case of 2014

The Florida Department of Health said today that a 50-year-old Miami–Dade County woman is the first person in the state with a confirmed locally acquired dengue fever case so far this year, the Associated Press (AP) reported.

The woman has fully recovered from the mosquito-borne disease, health officials said. Twenty-four imported cases have been confirmed in Florida in 2014 so far, but this is the first that was acquired in the state.

Last year the state reported 23 locally acquired dengue cases, the AP said.
Jul 9 AP story

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation 3MAccelerate DiagnosticsGilead 
Grant support for ASP provided by


bioMérieux

  Become an underwriter»